Financial Performance - Revenue for the year ended December 31, 2019, was RMB 997.5 million, representing an increase of 11.0% compared to RMB 899.0 million in 2018[10] - Profit attributable to owners of the company was RMB 75.4 million, a decrease of 6.0% from RMB 80.3 million in the previous year[10] - Basic earnings per share decreased by 8.0% to RMB 2.3 from RMB 2.5 in 2018[10] - The net cash flow from operating activities increased by 13.8% to RMB 321.1 million, up from RMB 282.1 million in 2018[10] - Total assets decreased by 1.1% to RMB 3,083.5 million from RMB 3,117.7 million in the previous year[10] - Cash and cash equivalents increased by approximately RMB 194.2 million to RMB 914.1 million as of December 31, 2019[50] - The company’s net cash position increased by approximately RMB 187.3 million to RMB 824.5 million as of December 31, 2019[50] - The income tax expense for the year was approximately RMB 17.3 million, down from RMB 24.9 million last year[48] - The company’s debt-to-equity ratio was 3.2% as of December 31, 2019, compared to 2.9% the previous year[50] - Administrative expenses decreased by approximately 17.4% from RMB 202.6 million to RMB 167.3 million this year[43] - Financing costs fell by about 52.7% from RMB 3.5 million to RMB 1.7 million this year[45] - Sales costs rose by approximately 30.5% from about RMB 586.5 million to approximately RMB 765.3 million, with raw material costs increasing by about 64.7% to approximately RMB 335.3 million[37] - Gross profit decreased by approximately 25.7% from about RMB 312.5 million to approximately RMB 232.2 million, resulting in a gross margin decline from about 34.8% to approximately 23.3%[40] Product Development and Diversification - The company plans to enhance the development of collagen protein products, health supplements, skincare products, and medical supplies to diversify its product offerings[15] - The company has made significant progress in product diversification, including the development of collagen rice noodles, collagen beverages, and bovine collagen ingredients[19] - The company is focusing on the development of collagen skincare products and has increased the variety of these products in response to market trends[19] - The company has completed the application materials for a collagen wound dressing as a Class III medical device, which is pending approval from the National Market Supervision Administration[19] - The company aims to accelerate its product diversification strategy in 2020, focusing on quality and market stability[20] - The company has entered the trial production phase for several new collagen food products, with some already on the market[26] - The company is committed to developing new products, including the "Luxeena" product line and the "Collagen Princess" new product, while accelerating the establishment and production of its Singapore base[66] - The company intends to obtain production permits for Class III collagen wound dressings and clinical trial approvals for high-activity collagen bone repair biomaterials within 2020[66] - The company will expand sales channels for medical collagen raw materials and Class I medical device products to generate economic benefits as soon as possible[66] Market Position and Competition - In 2019, the company maintained its leading position in the collagen casing market in China, despite challenges such as rising raw material prices and increased environmental regulations[22] - The company recognizes the impact of the COVID-19 pandemic on the Chinese economy but sees opportunities in the increasing demand for high-end collagen sausage casings as a substitute for expensive natural casings[62] - The company faces risks related to the stability and sufficiency of raw material supply, which can impact production volume and costs[153] - International competitors may establish production lines in China or reduce prices to penetrate the market, potentially affecting the company's pricing and profit margins[153] - The company has faced competition from substitutes like natural casings, which could adversely affect its business and profitability[153] Research and Development - The company has strengthened its research and development platform, hiring 12 high-level talents, including six PhDs and postdoctoral researchers, to enhance R&D capabilities[25] - The group has made substantial progress in the R&D of new products, with some products currently in trial production[28] - The group has received multiple patent approvals, with 81 patents granted and 16 pending approval from the China National Intellectual Property Administration[30] - The company has invested $5 million in R&D for new technologies aimed at improving production efficiency[140] Corporate Governance and Shareholder Engagement - The company has established a nomination committee to identify and recommend qualified candidates for the board, ensuring diversity in skills, experience, and perspectives[79] - The board structure separates the roles of the chairperson and CEO, with the chairperson overseeing the group's overall operations[78] - Independent non-executive directors have confirmed their independence and have been in their roles for over nine years, ensuring unbiased judgment[19] - The company emphasizes the importance of continuous professional development for all directors[94] - The board believes that its current structure supports effective operations and communication with shareholders[78] - The company has adopted a dividend policy that allows for annual dividends if the group is profitable and the operating environment is stable, with special dividends also possible[85] - The board will consider various factors before recommending any dividends, including the company's actual and expected financial performance, retained earnings, and debt-to-equity ratio[87] - The company has established a clear policy for the appointment and remuneration of external auditors[97] - The audit committee held four meetings during the year, with full attendance from all members[100] - The company emphasizes the importance of maintaining effective communication with investors through various channels, including seminars with media, analysts, and fund managers[124] Social Responsibility and Community Engagement - The company is actively participating in social welfare initiatives, including educational support and poverty alleviation[24] - The group reported a total charitable donation of RMB 2,899,000 during the year[171] Future Outlook and Strategic Plans - The company has outlined potential future business developments in its annual report, indicating a proactive approach to growth[152] - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share by 2025[138] - A strategic acquisition of a local competitor is in progress, which is anticipated to enhance production capacity by 40%[139] Shareholder Information - The company proposed a final dividend of HKD 0.02 per ordinary share and a special final dividend of HKD 0.04 per ordinary share, pending shareholder approval[159] - As of December 31, the company had distributable reserves totaling approximately HKD 210,525,000, with about HKD 193,829,000 recommended for the final dividend[168] - The company purchased 3,018,000 shares and canceled 4,098,000 shares during the year, with a total expenditure of HKD 1,364,840[165]

Financial Performance - Revenue for the six months ended June 30, 2019, was RMB 386.8 million, representing a 2.8% increase compared to RMB 376.2 million in the same period of 2018[14] - Profit attributable to owners of the company for the same period was RMB 31.4 million, a decrease of 15.7% from RMB 37.2 million in 2018[14] - Basic earnings per share for the first half of 2019 was RMB 0.97, down 14.9% from RMB 1.14 in the previous year[14] - Gross profit decreased by approximately 25.7% to about RMB 102,500,000, resulting in a gross margin decline from approximately 36.7% to about 26.5%[37] - Profit before tax decreased to RMB 32.448 million, a decline of 21.8% from RMB 41.522 million in the previous year[106] - Net profit for the period was RMB 26.885 million, representing a decrease of 17.2% compared to RMB 32.722 million in 2018[108] - Total comprehensive income for the period was RMB 29.097 million, down 9.4% from RMB 32.177 million in the same period last year[111] Cash Flow and Assets - Operating cash inflow for the six months was RMB 104.7 million, a decline of 9.2% from RMB 115.2 million in the same period last year[14] - Total assets as of June 30, 2019, amounted to RMB 3,012.3 million, compared to RMB 3,117.7 million at the end of the previous fiscal year[14] - Cash and cash equivalents increased by approximately RMB 5,500,000 to about RMB 725,400,000 as of June 30, 2019[48] - Total bank borrowings increased by approximately RMB 5,300,000 to about RMB 88,000,000, with a debt-to-equity ratio of 3.2%[50] - Current liabilities decreased to RMB 209.705 million from RMB 236.899 million at the end of 2018, indicating improved liquidity[118] - Non-current assets totaled RMB 1.610 billion, down from RMB 1.627 billion at the end of 2018[118] Operational Developments - The company plans to expand into collagen food, skincare products, and medical supplies, aiming to enhance its presence in the health and strategic emerging industries[17] - The company is focusing on the development of collagen technology and aims to upgrade the collagen industry while promoting its application in the health sector[20] - The group has developed new collagen products, including collagen rice noodles and solid/liquid collagen beverages, which have entered trial production and some are already on the market[22] - The group is actively developing new medical collagen products, including low endotoxin sterile medical-grade collagen and hydrophilic wound dressings[23] - The group has made significant progress in the development of collagen skincare products, with several new products in trial production[22] Cost Management - Sales cost increased by approximately 19.3% to about RMB 284,300,000, with raw material costs rising by about 34.1% to approximately RMB 109,400,000[36] - The company has been actively negotiating with raw material suppliers to manage rising costs, which have seen some reduction since the second quarter of 2019[19] - Financing costs decreased by approximately 86.3% to about RMB 383,000, following the repayment of most RMB-denominated loans[42] Shareholder Information - As of June 30, 2019, Ms. Zhou holds 2,241,006,000 shares, representing 69.37% of the company's equity[75] - The company has a significant shareholder, Futong, with 1,936,434,000 shares, accounting for 59.94% of the issued share capital[83] - The company has no plans to declare an interim dividend for the period due to anticipated capital expenditures and market expansion needs[68] Corporate Governance - The company has adopted the standard code of conduct for securities trading as per the listing rules[91] - The company has complied with all corporate governance code provisions during the reporting period[86] - The board of directors meets regularly to discuss significant operational matters affecting the group[87] Market Strategy - The group aims to accelerate the implementation of its product diversification strategy, focusing on the development of new products centered around collagen, targeting the health industry, which is projected to exceed RMB 16 trillion by 2030, three times the current market size[62] - The group plans to enhance product quality and market share while seeking overseas cooperation opportunities, with a focus on stabilizing its leading position in the collagen casing market[64] - The group will continue to develop collagen skincare products and improve product variety, ensuring alignment with contemporary societal demands[65] Taxation - The total tax expense for the period was RMB 5,563,000, compared to RMB 8,800,000 in the previous year[187] - The current tax expense in China decreased to RMB 6,836,000 from RMB 13,093,000 year-on-year[190] - The company continues to comply with the preferential corporate income tax rate of 15% for its subsidiary in Guangxi, China[188]

Financial Performance - Revenue for the year ended December 31, 2018, was RMB 899.0 million, a decrease of 10.8% from RMB 1,008.0 million in 2017[10] - Profit attributable to owners of the company increased by 16.7% to RMB 80.3 million, compared to RMB 68.8 million in the previous year[10] - Basic earnings per share rose by 19.0% to RMB 2.5, up from RMB 2.1 in 2017[10] - Net cash flow from operating activities decreased by 33.2% to RMB 282.1 million, down from RMB 422.4 million[10] - Total assets decreased by 5.4% to RMB 3,117.7 million, compared to RMB 3,294.0 million in 2017[10] - Gross profit increased by approximately 29.9% from RMB 240,700,000 to RMB 312,500,000, with gross margin rising from 23.9% to 34.8% due to higher average selling prices and lower sales costs[45] - Other income and gains rose by about 5.4% from RMB 34,900,000 to RMB 36,800,000, with foreign exchange gains of approximately RMB 3,700,000 recorded this year[47] - Selling and distribution expenses decreased by approximately 9.0% from RMB 43,600,000 to RMB 39,700,000, while the ratio of these expenses to revenue increased from 4.3% to 4.4%[48] - Administrative expenses increased by approximately 28.2% from RMB 158,100,000 to RMB 202,600,000, influenced by losses from the sale of aging equipment and amortization of intangible assets from the acquisition of Guangdong Shengchi[49] - Financing costs decreased significantly by approximately 59.4% from RMB 8,700,000 to RMB 3,500,000[54] - The company's attributable profit increased by approximately 16.7% from RMB 68,800,000 to RMB 80,300,000, with total selling and distribution expenses and administrative expenses for new product expansions amounting to RMB 15,700,000 and RMB 35,200,000 respectively[58] - As of December 31, 2018, cash and cash equivalents totaled approximately RMB 719,900,000, an increase of about RMB 48,700,000 from the previous year[59] - The company reported a loss of approximately HKD 5,910,000 for the year[181] - As of December 31, 2018, the company had distributable reserves totaling approximately HKD 334,617,000, with HKD 116,297,000 proposed for the final dividend[181] Market and Product Development - The company focused on expanding collagen technology applications and product diversification in the health industry[16] - The sales revenue of collagen casings decreased compared to the previous year due to slow growth in the domestic meat industry and market competition, as well as the impact of African swine fever[19] - The company has made progress in product diversification, with new collagen products such as collagen rice noodles, beef collagen ingredients, and collagen solid and liquid beverages entering trial production[23] - The company is actively developing 21 new products in the health supplement sector, including new nutrient soft capsules for pregnant women and iron supplements[23] - The average selling price of collagen casings increased despite a decrease in sales volume, due to a shift towards shorter shelf-life products and reduced discount promotions[28] - The company aims to stabilize and enhance product quality while expanding into new markets, focusing on collagen food, skincare, and medical products[25] - The company aims to accelerate product diversification, focusing on developing new products centered around collagen, including food, health products, cosmetics, pharmaceuticals, and medical materials[68] - The company plans to enhance the production and marketing of collagen rice noodles and accelerate the research and development of solid and liquid collagen beverages, aiming for new product launches[74] - The company is targeting to obtain clinical trial approval for high-activity collagen-based bone repair biomaterials within 2019 and aims to enhance sales of medical collagen raw materials and semi-finished products[75] - The company is actively developing new collagen-based medical materials, with high-activity collagen bone repair biomaterials entering the product technical index testing phase[33] Operational Efficiency - Inventory turnover days for raw materials increased by 4.3 days to 29.2 days, while finished goods and work-in-progress increased by 37.6 days to 338.4 days[10] - Accounts receivable turnover days increased by 15.5 days to 107.7 days, while accounts payable turnover days decreased by 40.9 days to 112.8 days[10] - The company is focusing on automation and intelligent upgrades of machinery to improve production efficiency and operational quality[31] - The company has successfully reduced raw material procurement prices through bulk purchasing, enhancing future product competitiveness[37] - The company is implementing new operational strategies aimed at improving efficiency, which is expected to reduce costs by D%[157] Governance and Compliance - The board held six meetings and five written resolutions this year, with attendance rates for individual directors ranging from 50% to 100%[85] - The company has adopted a board diversity policy to enhance operational quality, considering factors such as gender, age, and professional experience in board member selection[93] - The company has a dividend policy that allows for annual dividends and special dividends, contingent on profitability and stable operating conditions[95] - Any proposed final dividend must be approved by shareholders at the annual general meeting and cannot exceed the amount recommended by the board[99] - The board will regularly review the dividend policy and submit necessary amendments for approval[100] - Independent non-executive directors have confirmed their independence and are deemed to have integrity and independent judgment[86] - The company has not appointed a CEO, with daily operations managed by executive directors and department heads[89] - The nomination committee is responsible for identifying qualified candidates for the board, focusing on character, qualifications, and experience[90] - The company is considering the feasibility of appointing a CEO in the future[89] - The company adopted the standard code of conduct for securities trading as per the listing rules, ensuring compliance among all directors and senior management[101] - The board has proposed to enhance compliance measures and internal monitoring procedures to prevent future violations, including regular training for directors and management[102] - The audit committee held three meetings this year, with full attendance from its members[113] - The total fees paid to auditors for both audit and non-audit services amounted to RMB 2,723,000, with RMB 2,098,000 for audit services and RMB 625,000 for non-audit services[115] - The nomination committee held one meeting this year, reviewing the board's structure and diversity policies[119] - The company is committed to providing ongoing professional development for all directors to ensure they understand their responsibilities under applicable laws and regulations[106] - The board confirmed the effectiveness and adequacy of the group's risk management and internal control systems during the annual review[130] - The company has established a risk management framework involving the board, audit committee, and risk management team to effectively manage business risks[129] Shareholder Relations - The company emphasizes strong investor relations and communication through various channels, including seminars with media, analysts, and fund managers[133] - The financial director is responsible for preparing financial statements in accordance with Hong Kong accounting principles and ensuring compliance with relevant laws and regulations[126] - The company secretary ensures compliance with legal and regulatory requirements and facilitates communication between the board and shareholders[127] - The company has a clear policy for handling and disclosing inside information in accordance with the Securities and Futures Ordinance and Listing Rules[131] - The 2018 Annual General Meeting was held on May 23, 2018, with a board attendance rate of 6 out of 8 directors present[134] - The company emphasizes the importance of continuous dialogue with shareholders, particularly through annual general meetings[136] - The next annual general meeting is scheduled for May 22, 2019, indicating ongoing commitment to investor communication[137] - The company maintains a policy of timely updates to investors regarding business performance, adhering to regulatory requirements[137] - The company has established procedures for shareholders to submit inquiries and proposals to the board[139] - The company is committed to protecting shareholder interests and ensuring effective communication of relevant information[136] Human Resources - The total employee compensation and benefits expense for the year was approximately RMB 176.3 million, down from RMB 206.5 million in the previous year, with around 2,550 contract employees as of December 31, 2018[71] - The company recognizes the importance of human resources for long-term success and is dedicated to providing competitive compensation and ongoing training for employees[169] - The company will implement competitive compensation packages to attract and retain talent, ensuring smooth business operations amid ongoing expansion[71] - The remuneration of directors is determined based on their responsibilities, performance, and the company's performance[192] Share Repurchase and Dividends - The board proposed a final dividend of HKD 0.02 per ordinary share and a special final dividend of HKD 0.016 per ordinary share, pending shareholder approval[170] - The company repurchased a total of 5,716,000 shares in September 2018 at a price range of HKD 0.3900 to HKD 0.4050, totaling HKD 2,288,130[177] - In October 2018, the company repurchased 8,194,000 shares, with a total expenditure of HKD 3,287,960 at prices ranging from HKD 0.3900 to HKD 0.4100[177] - The company also repurchased 6,544,000 shares in November 2018, spending HKD 2,770,940 at prices between HKD 0.4000 and HKD 0.4400[177] - The company aims to enhance shareholder value by increasing net asset value per share and earnings per share through share repurchases[178]